{"count": 162, "results": [{"_id": "34264978", "pmid": 34264978, "pmcid": "PMC8282009", "title": "Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation", "journal": "PLoS One", "authors": ["Yan N", "Wang L", "Li Y", "Wang T", "Yang L", "Yan R", "Wang H", "Jia S"], "date": "2021-07-15T00:00:00Z", "doi": "10.1371/journal.pone.0254321", "meta_date_publication": "2021", "meta_volume": "16", "meta_issue": "7", "meta_pages": "e0254321", "score": 50279.63, "text_hl": "...Effects of oral @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ intervention on the parameters in @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@AS@@@.", "citations": {"NLM": "Yan N, Wang L, Li Y, Wang T, Yang L, Yan R, Wang H, Jia S. Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation PLoS One. 2021;16(7):e0254321. PMID: 34264978", "BibTeX": "@article{34264978, title={Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation}, author={Yan N and Wang L and Li Y and Wang T and Yang L and Yan R and Wang H and Jia S}, journal={PLoS One}, volume={16}, number={7}, pages={e0254321}}"}}, {"_id": "34163481", "pmid": 34163481, "pmcid": "PMC8215340", "title": "Metformin, Macrophage Dysfunction and Atherosclerosis", "journal": "Front Immunol", "authors": ["Feng X", "Chen W", "Ni X", "Little PJ", "Xu S", "Tang L", "Weng J"], "date": "2021-06-07T00:00:00Z", "doi": "10.3389/fimmu.2021.682853", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "682853", "score": 50277.15, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@, @DISEASE_Macrophage_Activation_Syndrome @DISEASE_MESH:D055501 @@@Macrophage Dysfunction@@@ and @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@", "citations": {"NLM": "Feng X, Chen W, Ni X, Little PJ, Xu S, Tang L, Weng J. Metformin, Macrophage Dysfunction and Atherosclerosis Front Immunol. 2021;12():682853. PMID: 34163481", "BibTeX": "@article{34163481, title={Metformin, Macrophage Dysfunction and Atherosclerosis}, author={Feng X and Chen W and Ni X and Little PJ and Xu S and Tang L and Weng J}, journal={Front Immunol}, volume={12}, pages={682853}}"}}, {"_id": "32099330", "pmid": 32099330, "pmcid": "PMC7006854", "title": "Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis", "journal": "Drug Des Devel Ther", "authors": ["You G", "Long X", "Song F", "Huang J", "Tian M", "Xiao Y", "Deng S", "Wu Q"], "date": "2020-02-03T00:00:00Z", "doi": "10.2147/DDDT.S233932", "meta_date_publication": "2020", "meta_volume": "14", "meta_issue": "", "meta_pages": "457-468", "score": 50277.094, "text_hl": "Thus, this research investigated the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and lncRNA @GENE_TUG1 @GENE_55000 @@@TUG1@@@ on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@AS@@@.", "citations": {"NLM": "You G, Long X, Song F, Huang J, Tian M, Xiao Y, Deng S, Wu Q. Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis Drug Des Devel Ther. 2020;14():457-468. PMID: 32099330", "BibTeX": "@article{32099330, title={Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis}, author={You G and Long X and Song F and Huang J and Tian M and Xiao Y and Deng S and Wu Q}, journal={Drug Des Devel Ther}, volume={14}, pages={457-468}}"}}, {"_id": "36077136", "pmid": 36077136, "pmcid": "PMC9456496", "title": "From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease", "journal": "Int J Mol Sci", "authors": ["Poznyak AV", "Litvinova L", "Poggio P", "Moschetta D", "Sukhorukov VN", "Orekhov AN"], "date": "2022-08-27T00:00:00Z", "doi": "10.3390/ijms23179738", "meta_date_publication": "2022 Aug 27", "meta_volume": "23", "meta_issue": "17", "meta_pages": "", "score": 50274.133, "text_hl": "From @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ to @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@: Potential of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for Management of @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@Cardiovascular Disease@@@", "citations": {"NLM": "Poznyak AV, Litvinova L, Poggio P, Moschetta D, Sukhorukov VN, Orekhov AN. From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease Int J Mol Sci. 2022 Aug 27;23(17):. PMID: 36077136", "BibTeX": "@article{36077136, title={From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease}, author={Poznyak AV and Litvinova L and Poggio P and Moschetta D and Sukhorukov VN and Orekhov AN}, journal={Int J Mol Sci}, volume={23}, number={17}}"}}, {"_id": "40758579", "pmid": 40758579, "title": "Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis.", "journal": "Am J Physiol Endocrinol Metab", "authors": ["Lee MK", "Cooney O", "Zhu Y", "Zhang Y", "Lin X", "Onda D", "Galic S", "Kemp BE", "Murphy AJ", "Loh K"], "date": "2025-08-04T00:00:00Z", "doi": "10.1152/ajpendo.00056.2025", "meta_date_publication": "2025 Aug 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50271.08, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ suppresses @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@ by dampening extramedullary myelopoiesis.", "citations": {"NLM": "Lee MK, Cooney O, Zhu Y, Zhang Y, Lin X, Onda D, Galic S, Kemp BE, Murphy AJ, Loh K. Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis. Am J Physiol Endocrinol Metab. 2025 Aug 4;():. PMID: 40758579", "BibTeX": "@article{40758579, title={Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis.}, author={Lee MK and Cooney O and Zhu Y and Zhang Y and Lin X and Onda D and Galic S and Kemp BE and Murphy AJ and Loh K}, journal={Am J Physiol Endocrinol Metab}}"}}, {"_id": "32667970", "pmid": 32667970, "pmcid": "PMC8064441", "title": "Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase", "journal": "Cardiovasc Res", "authors": ["Seneviratne A", "Cave L", "Hyde G", "Moestrup SK", "Carling D", "Mason JC", "Haskard DO", "Boyle JJ"], "date": "2021-04-23T00:00:00Z", "doi": "10.1093/cvr/cvaa171", "meta_date_publication": "2021 Apr 23", "meta_volume": "117", "meta_issue": "5", "meta_pages": "1295-1308", "score": 50270.766, "text_hl": "...@<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@-prevention by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ requires haematopoietic AMPK", "citations": {"NLM": "Seneviratne A, Cave L, Hyde G, Moestrup SK, Carling D, Mason JC, Haskard DO, Boyle JJ. Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase Cardiovasc Res. 2021 Apr 23;117(5):1295-1308. PMID: 32667970", "BibTeX": "@article{32667970, title={Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase}, author={Seneviratne A and Cave L and Hyde G and Moestrup SK and Carling D and Mason JC and Haskard DO and Boyle JJ}, journal={Cardiovasc Res}, volume={117}, number={5}, pages={1295-1308}}"}}, {"_id": "31955370", "pmid": 31955370, "pmcid": "PMC7048885", "title": "Metformin Delays the Development of Atherosclerosis in Type 1 Diabetes Mellitus via the Methylglyoxal Pathway", "journal": "Diabetes Ther", "authors": ["Liu A", "Li K", "Xu L", "Si M", "Teng G", "Li G", "Xue J", "Liang S", "Song W"], "date": "2020-03-01T00:00:00Z", "doi": "10.1007/s13300-020-00761-w", "meta_date_publication": "2020 Mar", "meta_volume": "11", "meta_issue": "3", "meta_pages": "633-642", "score": 50263.645, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Delays the Development of @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ in @DISEASE_Diabetes_Mellitus_Type_1 @DISEASE_MESH:D003922 @@@Type 1 Diabetes Mellitus@@@ via the @CHEMICAL_Pyruvaldehyde @CHEMICAL_MESH:D011765 @@@Methylglyoxal@@@ Pathway", "citations": {"NLM": "Liu A, Li K, Xu L, Si M, Teng G, Li G, Xue J, Liang S, Song W. Metformin Delays the Development of Atherosclerosis in Type 1 Diabetes Mellitus via the Methylglyoxal Pathway Diabetes Ther. 2020 Mar;11(3):633-642. PMID: 31955370", "BibTeX": "@article{31955370, title={Metformin Delays the Development of Atherosclerosis in Type 1 Diabetes Mellitus via the Methylglyoxal Pathway}, author={Liu A and Li K and Xu L and Si M and Teng G and Li G and Xue J and Liang S and Song W}, journal={Diabetes Ther}, volume={11}, number={3}, pages={633-642}}"}}, {"_id": "35278303", "pmid": 35278303, "title": "[A multidirectional effect of metformin].", "journal": "Pol Merkur Lekarski", "authors": ["Żyrek L", "Latocha M"], "date": "2022-02-22T00:00:00Z", "meta_date_publication": "2022 Feb 22", "meta_volume": "50", "meta_issue": "295", "meta_pages": "62-64", "score": 50261.03, "text_hl": "[A multidirectional effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@].", "citations": {"NLM": "Żyrek L, Latocha M. [A multidirectional effect of metformin]. Pol Merkur Lekarski. 2022 Feb 22;50(295):62-64. PMID: 35278303", "BibTeX": "@article{35278303, title={[A multidirectional effect of metformin].}, author={Żyrek L and Latocha M}, journal={Pol Merkur Lekarski}, volume={50}, number={295}, pages={62-64}}"}}, {"_id": "38196460", "pmid": 38196460, "pmcid": "PMC10772430", "title": "Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis", "journal": "Pak J Med Sci", "authors": ["Alatawi AM"], "date": "2024-01-01T00:00:00Z", "doi": "10.12669/pjms.40.1.6982", "meta_date_publication": "2024 Jan-Feb", "meta_volume": "40", "meta_issue": "1Part-I", "meta_pages": "209-213", "score": 50259.01, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ versus sodium glucose co-transporters inhibitors as first-line for @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic cardiovascular disease@@@: A meta-analysis", "citations": {"NLM": "Alatawi AM. Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):209-213. PMID: 38196460", "BibTeX": "@article{38196460, title={Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis}, author={Alatawi AM}, journal={Pak J Med Sci}, volume={40}, number={1Part-I}, pages={209-213}}"}}, {"_id": "37631325", "pmid": 37631325, "pmcid": "PMC10459002", "title": "Metformin Impedes Oxidation of LDL In Vitro", "journal": "Pharmaceutics", "authors": ["Rossmann C", "Ranz C", "Kager G", "Ledinski G", "Koestenberger M", "Wonisch W", "Wagner T", "Schwaminger SP", "Di Geronimo B", "Hrzenjak A", "Hallstöm S", "Reibnegger G", "Cvirn G", "Paar M"], "date": "2023-08-09T00:00:00Z", "doi": "10.3390/pharmaceutics15082111", "meta_date_publication": "2023 Aug 9", "meta_volume": "15", "meta_issue": "8", "meta_pages": "", "score": 50258.92, "text_hl": "The aim of this study was to investigate whether @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is capable of impeding the oxidation of LDL, a crucial step in the development of @DISEASE_Vascular_Diseases @DISEASE_MESH:D014652 @@@endothelial dysfunction@@@ and @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@. ", "citations": {"NLM": "Rossmann C, Ranz C, Kager G, Ledinski G, Koestenberger M, Wonisch W, Wagner T, Schwaminger SP, Di Geronimo B, Hrzenjak A, Hallstöm S, Reibnegger G, Cvirn G, Paar M. Metformin Impedes Oxidation of LDL In Vitro Pharmaceutics. 2023 Aug 9;15(8):. PMID: 37631325", "BibTeX": "@article{37631325, title={Metformin Impedes Oxidation of LDL In Vitro}, author={Rossmann C and Ranz C and Kager G and Ledinski G and Koestenberger M and Wonisch W and Wagner T and Schwaminger SP and Di Geronimo B and Hrzenjak A and Hallstöm S and Reibnegger G and Cvirn G and Paar M}, journal={Pharmaceutics}, volume={15}, number={8}}"}}]}